---
layout: lesson
<!---title:  Benefits<sup>13</sup><sup>,</sup><sup>14</sup> --->
---
<p align="center">
<!--img src="https://scnslabutsa.github.io/myhthelperEduContent/Images/AI1.png"/-->
<img src="https://scnslabutsa.github.io/myhthelperEduContent/Images/AAdoctorandpatient.PNG"/>
</p>

For women with hormone receptor-positive breast cancer, treatment with aromatase inhibitors (alone or after several years of tamoxifen) lowers the risk of:

* Breast cancer recurrence;
* Breast cancer in the opposite breast; and
* Death form breast cancer.

Among postmenopausal women with hormone receptor-positive breast cancer, aromatase inhibitors (alone or after tamoxifen) offer the same or slightly greater benefit compared to tamoxifen alone.

**References:**

<span style="font-size:15px;">Susan G. Komen, 2018. Aromatase Inhibitors.</span>

<span style="font-size:15px;">Breastcancer.org, 2018. Aromatase Inhibitors.</span>
